Discovering novel chemotherapeutic drugs for the third millennium

被引:112
作者
Garrett, MD [1 ]
Workman, P [1 ]
机构
[1] Inst Canc Res, CRC, Ctr Canc Therapeut, Sutton SM2 5NG, Surrey, England
关键词
contemporary drug discovery; novel molecular targets; small molecule mechanism-based drugs; high throughput bioscience assays; combinatorial chemistry; drug design and screening; molecular pharmacodynamics and imaging; hypothesis-testing clinical trials;
D O I
10.1016/S0959-8049(99)00280-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
There is enormous potential for the discovery of innovative cancer drugs with improved efficacy and selectivity for the third millennium. In this review we show how novel mechanism-based agents are being discovered by focusing on the molecular targets and pathways that are causally involved in cancer formation, maintenance and progression. We also shaw how new technologies, from genomics through high throughput bioscience, combinatorial chemistry, rational drug design and molecular pharmacodynamic and imaging techniques, are accelerating the pace of cancer drug discovery. The process of contemporary small molecule drug discovery is described and progress and current issues are reviewed. New and potential targets and pathways for therapeutic intervention are illustrated. The first examples of a new generation of molecular therapeutics are now entering hypothesis-testing clinical trials and showing activity. The early years of the new millennium will see a range of exciting new agents moving from bench to bedside and beginning to impact on the management and cure of cancer. (C) 1999 Published by Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:2010 / 2030
页数:21
相关论文
共 243 条
  • [1] Adams J, 1999, CANCER RES, V59, P2615
  • [2] The p53 network
    Agarwal, ML
    Taylor, WR
    Chernov, MV
    Chernova, OB
    Stark, GR
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (01) : 1 - 4
  • [3] Depletion of intracellular Ca2+ stores, phosphorylation of eIF2α, and sustained inhibition of translation initiation mediate the anticancer effects of clotrimazole
    Aktas, H
    Flückiger, R
    Acosta, JA
    Savage, JM
    Palakurthi, SS
    Halperin, JA
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (14) : 8280 - 8285
  • [4] Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study
    Andreyev, HJN
    Norman, AR
    Cunningham, D
    Oates, JR
    Clarke, PA
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (09) : 675 - 684
  • [5] [Anonymous], 1998, The World Health Report
  • [6] The drug discovery factory: An inevitable evolutionary consequence of high-throughput parallel processing
    Archer, R
    [J]. NATURE BIOTECHNOLOGY, 1999, 17 (09) : 834 - 834
  • [7] Cell-cycle arrest and inhibition of Cdk4 activity by small peptides based on the carboxy-terminal domain of p21(WAF1)
    Ball, KL
    Lain, S
    Fahraeus, R
    Smythe, C
    Lane, DP
    [J]. CURRENT BIOLOGY, 1997, 7 (01) : 71 - 80
  • [8] BARING M, 1997, SCIENCE, V278, P1035
  • [9] Bartkova J, 1997, Prog Cell Cycle Res, V3, P211
  • [10] IDENTIFYING SMALL-MOLECULE LEAD COMPOUNDS - THE SCREENING APPROACH TO DRUG DISCOVERY
    BEVAN, P
    RYDER, H
    SHAW, A
    [J]. TRENDS IN BIOTECHNOLOGY, 1995, 13 (03) : 115 - 121